ArticleCardiovascular diagnosis and therapy2026
Left ventricular flow components and myocardial deformation following treatment for hypertrophic obstructive cardiomyopathy: a retrospective cardiac magnetic resonance-based cohort of mavacamten
Article in Cardiovascular diagnosis and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Response to: "Comparative hemodynamic effects of mavacamten and septal myectomy in HOCM: important methodological considerations".Cardiovascular diagnosis and therapy · 2026Article
- Comparative hemodynamic effects of mavacamten and septal myectomy in HOCM: important methodological considerations.Cardiovascular diagnosis and therapy · 2026Article
Corrections and comments
- Commented on by
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The differential therapeutic effects of the novel medication mavacamten and septal myectomy in patients with hypertrophic obstructive cardiomyopathy (HOCM) remain unclear. This study combined cardiac magnetic resonance (CMR) feature tracking (CMR-FT) with four-dimensional flow (4D-flow) imaging to compare the differential improvements in myocardial deformation function and ventricular hemodynamics achieved by these two treatments. Methods: This retrospective study reviewed CMR images from all HOCM patients treated with mavacamten or septal myectomy (February 2021-May 2023) at baseline and 30 weeks (during continued mavacamten or post-operation), along with 10 healthy volunteers without cardiovascular disease or risk factors. CMR parameters included: FT-based left ventricular (LV) global longitudinal strain (GLS), global circumferential strain (GCS), and global radial strain (GRS); and LV flow components derived from 4D-flow, including direct flow (DF), retained inflow (RIF) component, delayed ejection flow (DEF), and residual volume (RV). Intra-group differences were compared using paired t-tests, while inter-group differences were assessed using independent samples Results: This single-center study analyzed CMR images from 10 HOCM patients treated with mavacamten, 10 HOCM patients treated with myectomy, and 10 healthy volunteers. From baseline to 30 weeks, the mavacamten group and myectomy group showed similar degrees of improvement in LV structure, function, and myocardial deformation (mavacamten Conclusions: For HOCM patients, short-term treatment with either mavacamten or septal myectomy yields comparable improvements in LV structure, function, and myocardial deformation. However, septal myectomy appears to confer a modest advantage in the short-term improvement of LV flow components. It will be essential to further investigate the long-term 4D-flow CMR outcomes in HOCM patients following treatment. Furthermore, reduced DF and elevated RV may be important hemodynamic characteristics of HOCM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.